|Assessment Process Complete
|In combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Evaluation Recommended
|Full submission received from Applicant
|NCPE assessment completed
|NCPE assessment outcome
|Reimbursement Not Recommended at the Submitted Price.
The HSE has approved reimbursement following confidential price negotiations December 2015.